Hikma rises as it ups full year guidance on strong first-half

15 August 2018

Hikma Pharmaceuticals (LSE: HIK) saw its London-listed shares rise as much as 10% to 1,812.5 pence in early trading, after the Jordan-based generics drugmaker reported strong interim results for the six months ended June 30, 2018.

Group revenue of $989 million, were up 11% and in constant currency up 10%.
Operating profit of $174 million was up 54%.
Core group operating profit of $214 million was up 22% and up 23% in cc.
Core basic earnings per share of $0.61 were up 35% and up 38% in cc.
Basic earnings per share of $0.44.0 rose 53% and were up 57% in cc.
Full-year 2018 guidance raised for Injectables and Generics businesses and reiterated for Branded business.

Hikma expects full-year revenue at its injectables business to be $775 million to $825 million, higher than its prior forecast of $750 million to $800 million, while margins are seen in the mid to high 30s percent, up from low-to-mid 30s.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK